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Expression of molecular mediators of apoptosis
and their role in the pathogenesis of lower-
extremity varicose veins
Enrico Ascher, MD, Theresa Jacob, PhD, Anil Hingorani, MD, Boris Tsemekhin, MD, and Yilmaz
Gunduz, MD, Brooklyn, NY
Purpose: In an earlier study, we observed a significant decrease in apoptosis in varicose veins, as compared with healthy
veins, indicating that deregulated apoptosis plays a role in the pathogenesis of varicosities. In addition, significant dif-
ferences were noted in the expression and subcellular localization of the cell cycle regulatory protein, cyclin D1 in varix
tissues, as compared with controls. Because cell cycle checkpoint controls are linked to the signaling and execution of
apoptotic cascades, we examined the expression of bcl-2 family members bax and bcl-x, known molecular mediators of
apoptosis, and that of poly (ADP-ribose) polymerase (PARP), a downstream substrate of DNA cleavage.
Methods: Twenty varicose vein specimens were retrieved from 20 patients (10 men, 10 women; mean age, 53.6 ± 4.7
years) undergoing lower-extremity varicose vein excision. Healthy greater saphenous vein segments (n = 27) were
obtained from 27 patients (14 men, 13 women; mean age, 59.5 ± 2.4 years) undergoing infrainguinal arterial bypass
grafting surgery. All tissues were distal portions. As per CEAP classification for chronic lower-extremity venous dis-
ease, most of the patients were in class 2 for clinical signs (n = 11); some patients were in class 3 (n = 4) or class 4 (n
= 4), and only one patient was in class 5. Five 5-µm thick sections from formalin-fixed, paraffin-embedded specimens
were used as a means of immunohistochemically localizing the expression of bax, bcl-x, and PARP, and 10 random
high-power fields per section were evaluated by two independent reviewers blinded to the clinical findings. Statistical
analyses were conducted by means of χ2, analysis of variance, Student and Fisher exact t tests with StatView software.
Results: Immunoreactivity to pro-apoptotic bax was significantly higher in the normal veins (P < .001). Cytoplasmic
expression of bcl-x was prominent in the cells of the vasa vasorum in both varicose and healthy veins. PARP expression
was diminished in the varicose vein group, with 2.8 ± 0.7 (P = .01) and 1.4 ± 0.5 (P = .05) cells per high-power field
in the intima and media, respectively. Neither bax nor PARP was noted in the adventitia of varicose veins, although
their expression was detected in this layer of the control group (P < .001).
Conclusion: The entry of smooth muscle cells into the apoptotic pathway may be regulated by the induction of bax in
this model, because there is significant presence of this pro-apoptotic protein in healthy veins. Both bax and PARP are
downregulated in varicose veins, as compared with healthy veins, and this may play a significant role in the pathogen-
esis of varicose veins. (J Vasc Surg 2001;33:1080-6.)
The etiology of varicose veins of the lower extremities
is unclear, primarily because there have been limited inves-
tigations into the molecular mechanisms that could poten-
tially lead to dilatation of the vein wall.1 Because a family
history can be elicited from most patients with varicose
veins, it is possible that genetic factors play a role in the
development of this condition. Cell cycle dysfunction and
deregulated turnover of the cells within the vein wall may
contribute to the remodeling observed in varicose veins.2
In an earlier investigation, we found significant differences
in the levels of apoptosis between healthy and varicose
veins, indicating that deregulated programmed cell death
may be one possible cause for the pathogenesis of varicose
veins.3 Apoptosis is a multifactorial phenomenon, and
there exist multiple death pathways inducible by different
stimuli that can be positively or negatively regulated by the
members of the expanding bcl-2 family. Although bcl-2
and bcl-xL are negative modulators, rescuing cells from
undergoing programmed cell death, bax and bcl-xS are
inducers of apoptosis. Bax and bcl-2 are able to form
homodimers (bax/bax) and heterodimers (bax/bcl-2) in
vivo that are associated with cell death and cell survival,
respectively.4-6 Bax is also a downstream effector of the
tumor suppressor gene, p53, and was the first pro-
apoptotic target of p53 to be discovered. It is known to
promote growth arrest via the p53 pathway. Although
human bax has approximately 21% amino acid sequence
identity with bcl-2, the activity of bax is such that when it
is overexpressed, it is able to counter bcl-2 activity by pro-
moting apoptosis.7 Bax expression can activate a common
pathway of apoptosis either caspase-dependent or caspase-
independent.8
Additionally, proteolytic cleavage of key substrates is an
important biochemical mechanism underlying the apop-
totic process.9 Poly (ADP-ribose) polymerase (PARP) is a
macromolecular downstream substrate of apoptosis. PARP,
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the first protein noted to be degraded into specific frag-
ments in apoptotic cells, is an enzyme involved in genome
surveillance and DNA repair.10 Cleavage of PARP into its
89-kDa (85-kDa) form, considered a hallmark of apopto-
sis,11 results in the separation of its important functional
domains from the rest of the molecule.12
The purpose of the current study was to understand
the molecular mechanisms of cell turnover and its role in
the pathogenesis of varicose veins. We examined the
expression of bcl-2 family members bax and bcl-x in
healthy vein specimens and varicose vein specimens. We
also investigated the changes in the immunocytochemical
distribution and subcellular localization of PARP, a down-
stream substrate of DNA cleavage, to define the role of
apoptosis in the vein wall.
MATERIALS AND METHODS
Patients. Twenty-seven healthy greater saphenous
vein (GSV) specimens were obtained from 27 patients
(14 men, 13 women) who were undergoing infrain-
guinal arterial bypass grafting surgery, and they were
found to be free of acute or chronic inflammation by
means of hematoxylin and eosin staining. All GSV seg-
ments were from the distal calf region. Three of the
specimens were from healthy tributaries of the GSV.
Twenty varicose vein specimens were retrieved from 20
patients (10 men, 10 women) who were undergoing
lower-extremity varicose vein excision. The operative
indications were pain, edema, venous stasis disease, or
cosmetic purposes. All patients had had symptoms for 6
months or longer. Patient demographics and clinical risk
factors are given in Table I. As per CEAP classification
for chronic lower-extremity venous disease, most of the
patients were in class 2 for clinical signs (n = 11); some
patients were in class 3 (n = 4), some patients were in
class 4 (n = 4), and one patient was in class 5. All
patients were characterized as having primary varicosi-
ties, except one patient who had secondary varicosities.
Preoperative lower-extremity venous duplex ultra-
sound scanning assessment was performed on all patients,
and both the superficial and the deep venous systems were
studied. A standard method of examination was per-
formed on each patient beginning at the common femoral
vein and continuing distally to the tibial and peroneal
veins. Transverse and longitudinal views of the veins were
obtained to determine venous flow with respiration and
augmentation maneuvers and to document echogenic sig-
nals within the vein lumen to identify thrombus. All
patients from the varicose vein group exhibited reflux in
the GSV. In 7 patients, the deep venous system was also
affected, 5 with reflux and 2 with reflux and evidence of
concomitant nonocclusive deep venous thrombosis. Two
patients in the varicose vein group had duplex evidence of
GSV thrombosis. Although in all patients the GSV exhib-
ited reflux, in 40% of the cases the lesser saphenous vein
was also affected. The deep venous segments, common
femoral, superficial femoral, and popliteal veins exhibited
reflux in 20% of the cases. Reflux was demonstrated in the
iliac vein in only two patients and in the deep femoral vein
in one patient. The control group consisted of patients
without a history of venous disease in whom no evidence
of reflux was demonstrated by means of duplex scans.
Venous thrombosis was not demonstrated, histologically
or by means of duplex examination, in any patient. This
investigation was undertaken with the approval of the
institutional review board of Maimonides Medical Center
and with the informed written consent of the patients.
Tissue specimens. All vein specimens were fixed in 10%
neutral buffered formalin solution containing approximately
3.7% formaldehyde (wt/vol), for 6 to 12 hours (occasion-
ally for as long as 18 hours) and paraffin embedded. Five
portions of each vein specimen were embedded per paraffin
block. Transversal tissue sections 5-µm thick were mounted
on 3-aminopropyltriethoxysilane-coated slides. Each slide
contained five sections of one vein specimen.
Histology. Routine hematoxylin and eosin staining was
performed for histologic evaluation of the specimens.
Gomori’s one-step trichrome staining was used as a means
of identifying changes in collagenous connective fibers and
differentiating between collagen and smooth muscle fibers
in both healthy and varicose vein specimens. Verhoeff’s elas-
tic tissue staining (with van Gieson stain to counterstain)
was performed as a means of assessing the pathologic
changes in the elastin network in all the veins included in the
study.
Immunohistochemistry. The primary antibodies
used in this study were (1) rabbit monoclonal bax
(Oncogene Research Products, Cambridge, Mass); (2)
goat monoclonal bcl-x (Santa Cruz Biotechnology, Santa
Cruz, Calif); and (3) rabbit polyclonal PARP (Santa Cruz
Biotechnology). Serial formalin-fixed paraffin-embedded
tissue sections were deparaffinized and rehydrated by
sequential immersions in four changes of xylene followed
by baths of 100%, 95%, 70%, and 50% ethanol and phos-
phate-buffered saline (PBS). After protease digestion, the
antigens in the venous tissues were unmasked in 0.57
mol/L urea (no antigen retrieval for PARP) by means of
heat treatment in a pressure cooker at 9 minutes full pres-
sure, followed by a 25-minute cool down. After cooling,
the endogenous biotin activity in the tissue sections was
blocked by immersing the slides in a dilute egg white solu-
tion, for 15 minutes at room temperature (RT). After sev-
eral rinses with tap water, the slides were placed in skim
Table I. Clinical risk factors
Healthy veins Varicose veins P
(n = 27) (n = 20) value
Age ± SEM (y) 59.5 ± 2.4 53.6 ± 4.7 NS
Men:women (24:23) 14:13 10:10 .57
Diabetes mellitus (n = 8) 6 2 .29
Hypertension (n = 8) 5 3 .56
Tobacco use (n = 5) 4 1 .32
NS, Not significant.
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Fig 1. Representative photomicrographs of immunohistochemical analysis for expression of apoptosis-related molecules. Formalin-fixed
paraffin-embedded tissues were processed for localization of bax and PARP, as described in the methods section. Brown staining (perox-
idase) indicates immunopositivity. A, Negative control; venous tissue sections were processed for immunohistochemistry with omission of
primary antibodies (original magnification, 200×). B, Varicose vein section demonstrating expression of bax in smooth muscle cells (orig-
inal magnification, 400×). C, Control vein tissue stained with antibody for bax. Note transmural expression of bax in venous wall (origi-
nal magnification, 100×). D, Healthy vein section illustrating the expression of bax in the vasa vasorum of adventitial layer (original
magnification, 400×). E, Varicose vein tissue demonstrating immunoreactivity to PARP in media (original magnification, 400×). F, Vasa
vasorum of healthy vein tissue showing expression of PARP (original magnification, 400×). G, Positive control for PARP expression
(tumor tissue; original magnification, 100×). H, Positive control for bax expression (tumor tissue; original magnification, 400×).
milk for 15 minutes at RT and rinsed with tap water and
PBS containing 0.0001% Tween 20 (PBS/Tween). Tissue
sections were incubated with antibodies for bax, at a dilu-
tion of 1-to-20, bcl-x, at a dilution of 1-to-2000, and
PARP, at a dilution of 1-to-10, for 1 hour at RT, followed
by rinses with PBS/Tween. Prediluted biotinylated link
antibodies, antigoat (DAKO, Carpinteria, Calif) for goat
primary antibody, and antirabbit (Scytek, Logan, Utah) for
rabbit primary antibody were added to the specimens as
per the manufacturers’ instructions and incubated for 30
minutes at RT. The endogenous peroxidase activity was
quenched by immersing the slides in 0.3% H202 in PBS for
10 minutes. The bound primary antibodies were amplified
by LSAB2-horseradish peroxidase-labeled streptavidin
complex and detected with 3,3´-diaminobenzidene (DAB)
substrate (DAKO). The reaction products were developed
in DAB solution, and stain development was stopped by
immersing the slides in tap water and then in PBS/Tween.
Chromogenic enhancement was accomplished by incubat-
ing the specimens in 0.5% copper sulphate in PBS/Tween
for 5 to 8 minutes at RT. Subsequently, the slides were
counterstained with Mayer’s hematoxylin for 1.5 minutes.
Tissue samples were dehydrated and coverslipped with
mounting medium. A section of a multitumor sandwich
block (containing as many as 79 different tumors in 1
block), placed on one end of each slide, served as a positive
control. The specificity of the immunohistochemical reac-
tions was checked by omitting the primary antibody and
substituting it with an unrelated antibody at the same dilu-
tion. For tissue authentication, serial sections of each spec-
imen were also stained with hematoxylin and eosin.
Quantification. The expression of proteins was evalu-
ated according to staining intensity and immunocytochem-
ical distribution-cytoplasmic and nuclear staining, based on
the results of two independent investigators who were
blinded to the clinical findings. The entire section for each
specimen was scanned by the use of the 20× magnification
to estimate the subjective level of staining. Cells that stained
positive for bax, bcl-x, and PARP in the intima, media,
adventitia, and vasa vasorum were counted manually at
400× magnification and quantified in 10 random fields per
section. Five sections per specimen were evaluated.
Statistical analysis. For immunohistochemistry, the
data were expressed not only as cells per high-power field
(hpf) but also as percentage of cells with nuclear and cyto-
plasmic expression of the antigen. The data obtained were
analyzed by means of the Student t and χ2 tests. The
Fisher exact test and analysis of variance were used as a
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means of comparing the results obtained in the different
groups. A P value less than .05 was considered to be sta-
tistically significant. Statistical analyses were performed
with StatView (SAS Institute, Cary, NC) software.
RESULTS
Histology
Consistent with our previous report and those of
other investigators, varicose vein specimens exhibited a
more disorganized architecture than healthy veins.
Conspicuously decreased collagen matrix in varicose veins,
as compared with healthy veins, was shown by means of
Gomori’s trichrome staining. Increased degradation of
elastin network was demonstrated by means of Verhoeff’s
elastin staining. Smooth muscle cells (SMCs) of varicose
vein specimens were enlarged and appeared to have lost
their elongated morphology.
Molecular mediators of apoptosis
Bax expression. It was revealed by means of
immunohistochemistry that 36.32% ± 9.80% of cells
were positive for bax expression in varicose vein tissues,
as compared with 22.35% ± 4.77% in normal veins (Fig
1, B, C, and D). Antibody to bax exhibited cytoplasmic
and nuclear immunoreactivity in venous tissues. Table II
shows the subcellular localization of bax expression.
Although the expression of this pro-apoptotic protein
appeared transmural in nature in the control vein walls, it
was significantly absent in the adventitia of the varicose
veins (P < .001). Fig 2 demonstrates the number of cells
found to be positive for bax per hpf in each layer of the
wall. These data do not necessarily correlate with the per-
centage of cells staining positive for bax, because there
are differences in the total number of cells per hpf in vari-
cose vein tissue as compared with those in control vein
tissue. This may be a result of the previously noted
changes in cell size and vessel wall architecture. No cells
in the vasa vasorum of the varicose veins demonstrating
immunopositivity for bax could be detected. However,
control veins showed 6.5 ± 4.37 cells per hpf (P < .001)
that were positive for bax expression. Higher numbers of
SMCs were found to be positive for bax protein in vari-
cose veins than in control veins (P < .001).
Bcl-x expression. Bcl-x expression was found to local-
ize only to the cytoplasm with a granular pattern. There
were some cells in the control veins and a few in the varix
tissues that demonstrated immunoreactivity to bcl-x.
Table II. Immunocytochemical distribution and subcellular localization of bax (% positive cells)
Intima Media Adventitia
Staining pattern Cytoplasmic Nuclear Cytoplasmic Nuclear Cytoplasmic Nuclear
Normal vein 16.07 ± 2.94 6.50 ± 1.99 8.34 ± 4.18 5.68 ± 4.01 9.45 ± 5.51 9.60 ± 6.13
Varicose vein 12.66 ± 6.12 9.40 ± 5.76 15.18 ± 4.75 5.90 ± 4.73 0 0
P value .37 .32 .12 .62 < .01 < .01
Although it appeared that bcl-x expression was more
prominent in the control veins than the diseased tissue,
the signal was weak, and we could not objectively quantify
this. Bcl-x expression was markedly stronger in the SMCs
of the vasa vasorum, with more positive cells in the con-
trol veins, but otherwise it was difficult to clearly distin-
guish between positive and negative cells.
Expression of death substrate, PARP. The antibody
to PARP localized in the cytoplasm and the nucleus in all
tissues (Fig 1, E and F). The amount of cells positive for
PARP in the varicose vein tissues was 37.2% ± 3.44%,
whereas in the healthy vein tissues it was 46.1% ± 2.71%.
Table III shows the subcellular localization of PARP
expression. Fig 3 demonstrates the number of cells posi-
tive per hpf in each layer of the wall. Because of differences
in cell sizes, the number of cells per hpf do not necessarily
correlate with the percentage of positive cells.
Significantly, the expression of PARP was not detected
in the adventitia or in its vasa vasorum in varicose veins.
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However, PARP was detected in the control veins, with a
mean of 20.75 ± 2.56 cells per hpf (P < .001).
The data exhibit no significant differences in the
expression of the apoptosis-related proteins among the
various subgroups of varicose veins studied.
DISCUSSION
This study compared the presence of apoptosis-related
proteins that affect cell turnover in healthy vein tissues and
varicose vein tissues. We observed that the immunoreac-
tivity to pro-apoptotic bax was significantly higher in the
healthy veins (cells per hpf, P < .001). PARP expression
was diminished in the varicose vein group as compared
with that in control veins. Neither bax nor PARP was
detected in the adventitia of varicose veins, although their
expression was noted in this layer of the control group (P
< .001). Because this layer may contribute significantly to
the strength of the vessel, it is not surprising that the most
pronounced changes in apoptosis are found here.
Fig 2. Graph demonstrating number of cells per high-power field
that stain positive for bax in venous wall layers of control and vari-
cose veins. All values are expressed as mean ± SEM.
Fig 3. Number of cells per high-power field that are immunoreac-
tive to PARP antibody in intima, media, and adventitia of healthy
veins and varicose veins. All values are expressed as mean ± SEM.
Table III. Immunocytochemical distribution and subcellular localization of PARP (% positive cells)
Intima Media Adventitia
Staining pattern Cytoplasmic Nuclear Cytoplasmic Nuclear Cytoplasmic Nuclear
Normal vein 13.70 ± 7.64 9.6 ± 5.4 3.23 ± 2.66 7.33 ± 4.60 9.78 ± 2.88 29.30 ± 3.17
Varicose vein 8.05 ± 4.55 5.13 ± 2.70 11.67 ± 6.27 0 0 0
P value .16 .16 .02 < .01 < .01 < .01
These data serve to support our earlier investigation
on the genetic factors and molecular mechanisms in the
pathogenesis of varicose veins. Earlier work by our group
demonstrated the presence of apoptosis in the venous tis-
sue. Not only were there higher levels of apoptotic bodies
in the adventitia of control veins than in the other layers,
but also programmed cell death was downregulated in
varicose veins. Actually, this observed DNA cleavage is a
rather late stage of programmed cell death and a culmina-
tion of various molecular events in the apoptotic cascade.
Apoptosis occurs in at least two stages.13 After a signal,
which may be either intrinsic or extrinsic to the cell, the
cell enters a committed phase. This is terminated in cell
autonomous fashion by a transition to a final execution
phase, which includes DNA fragmentation and is brief and
decisive.14 We used the expression of the bcl-2 family pro-
teins to detect the committed phase, which influences the
cell cycle turnover.
In earlier reports on the pathology of lower-extremity
varicose veins, SMCs phenotypically appear transformed
from contractile to secretory cell types.15 Pappas et al16
suggested that enhanced pRb phosphorylation in varicose
veins may mediate SMC dedifferentiation. It is possible
that vein wall cells may become dysfunctional because of
the deregulation of the cell cycle and apoptosis. Because
apoptosis plays a major role in tissue homeostasis and cell
number maintenance, it influences cell turnover in the
vein wall. Deregulated apoptosis could give rise to redun-
dant cells, which may get transformed or dedifferentiated
into an abnormal phenotype. Deregulated apoptosis has
been implicated as a fundamental pathogenic mechanism
in a variety of human diseases in which faulty DNA repair
mechanisms and cell cycle alteration are involved7,17,18
and may play a role in the etiology of varicose veins.
Of significance and corroborating our previous find-
ing of decreased apoptosis is the total absence of
immunopositivity for bax in the adventitia of all varicose
vein specimens. This is in contrast to findings in the media
and intima. Because bax is a known apoptosis-inducer, its
downregulation in this venous disorder may be meaning-
ful. Kockx et al14 reported that fatty streaks in carotid
endarterectomy specimens express bax and are susceptible
to undergoing apoptosis. However, Brousset et al19 found
no correlation between bax expression and the presence of
apoptosis in Reed-Sternberg cells of Hodgkin’s disease, in
which they described high levels of expression of bax.
Bcl-x was demonstrated in our study to have an overall
weak cytoplasmic expression. There were strong signals in
the vasa vasorum of all the veins studied. Moreover, there
seemed to be more positive immunostaining in the control
veins. The results of the staining for the immunocyto-
chemical distribution of bcl-x were inconclusive, because
we could not quantify its expression. This may be because
of the lack of specificity of the antibody used to the cell
types in the vein tissue or some experimental artifact.
However, whether the bcl-x immunoreactivity detected
here represents the anti-apoptotic bcl-xL or the pro-
apoptotic bcl-xS forms of the protein is not known. Also,
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the expression of bcl-x and bcl-2 seems to be difficult to
detect in blood vessels. In an earlier study, we could not
detect significant differences in the expression of anti-apop-
totic bcl-2 in varicose and healthy veins. Other investigators
have reported a lack of immunopositivity for bcl-2 in ather-
osclerotic lesions of primary and restenotic types.14,20
Our data indicate a decreased presence of PARP in the
varix specimens, as compared with the control group. This
is the first study that looked at PARP expression in the
venous tissue. We could not detect this death substrate in
the adventitia of varicose veins, although positive signals
were significantly higher in the adventitia of healthy veins,
including in the vasa vasorum. This is an important finding
because PARP cleavage indicates that caspase activity is
responsible for programmed cell death in the veins. PARP
was not present in the adventitia of varicose veins. This was
in contrast to the increased immunopositivity in the SMCs
of the media of varicose veins, as compared with that in the
control veins, suggesting a differential expression.
Cell turnover and signaling events in vascular remod-
eling and development of varicosities has not been the
focus of much investigation. In an earlier study, we
demonstrated increased nuclear presence of the cell cycle
regulatory protein, cyclin D1, in varix tissues, whereas its
cytoplasmic expression was significantly diminished when
compared with that in normal veins. We tried to elucidate
the molecular mechanisms involved in the pathogenetic
process of varix formation and cell cycle deregulation by
studying the expression of modulators of apoptosis and
one of the key death substrates in normal and varicose
veins. We were convinced that localizing the expression of
bax, bcl-x, and a downstream substrate of apoptosis,
PARP, and their spatial organization and topographical
relationship with immunohistochemical techniques had
more potential than quantifying their total content in the
tissue. Perhaps because of the small and varying number of
specimens in the CEAP-classified subgroups of varicose
veins in this study, no significant differences in the expres-
sion of these proteins were noted among them. This study
does not address whether apoptosis is the cause or effect
of varicose vein formation, because we could not obtain
any “potential” varicose vein specimens. Further studies
are necessary to answer this question. Moreover, although
not examined in this report, other bcl-2 family members
that interact to form heterodimers, such as the recently
described bag-1, bim, noxa, and other proteins may be
involved in the regulation of apoptosis in the vein wall.
Therefore, further work is mandatory to better elucidate
the molecular pathways that lead to the pathogenesis of
varicose veins.
Our data indicate that the process of programmed cell
death is inhibited in varicose veins. The significantly
diminished expression of bax in varicose vein samples, as
compared with that in the control vein samples, correlates
with this hypothesis. The entry of SMCs into the apop-
totic pathway may be regulated by the induction of bax in
this model. Because bax is an important pro-apoptotic
downstream effector of p53 molecule, it is likely that one
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of the apoptotic cascades in this model follows p53 activa-
tion. Expression of PARP indicates caspase activation lead-
ing to apoptosis. Both bax and PARP are downregulated
in varix tissues, and this may play a significant role in the
pathogenesis of varicosities. There was no detectable
expression of either bax or PARP in the adventitia of vari-
cose veins, corroborating our earlier finding that apopto-
sis is reduced in this layer. Bcl-x signals are stronger in the
vasa vasorum of the veins. This may have a role in the mo-
lecular pathways that cause this venous disorder. Further
work is warranted to elucidate the cause-effect relationship
of apoptosis in the pathogenesis of varicose veins and to
unravel the signaling events and molecular cross-talks
therein. We are currently in the process of establishing an
in vitro model of venous tissue and examining the effects
of certain inducers of apoptosis. The results from these
investigations would lead to new insights and may elabo-
rate on better treatment modalities for this disorder.
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